F-group (family)
213.1.1.29 Acetyltransf_9
Ligands and drugs
182
Member domains
129
with ligand contacts (≤ 4 Å)
70.9% of members
122
with DrugDomain annotations
67.0% of members
98
with a DrugBank compound
53.8% of members
Aggregated over all current member domains of this group. Drug annotations come from DrugDomain; buffers and crystallization additives are excluded from the tables below.
Chemical profile
Chemical profiles are computed for X-groups. 213.1.1.29 belongs to X-group 213 Nat/Ivy, which binds 9.0 ligand superclasses per 20 proteins, broader than 80% of the 256 X-groups with enough proteins to compare. View its chemical profile →
DrugBank compounds
| DrugBank | PDB ligand | Name | Domains |
|---|---|---|---|
| DB01992 | COA | Coenzyme A | 33 |
| DB01421 | PAR | Paromomycin | 6 |
| DB01694 | TAR | D-tartaric acid | 5 |
| DB00479 | AKN | Amikacin | 2 |
| DB00684 | TOY | Tobramycin | 2 |
| DB00450 | USS | Droperidol | 1 |
| DB00502 | GMJ | Haloperidol | 1 |
| DB00608 | CLQ | Chloroquine | 1 |
| DB00878 | XC9 | Chlorhexidine | 1 |
| DB01131 | XEW | Proguanil | 1 |
| DB02736 | ACM | Acetamide | 1 |
| DB05636 | YMZ | (+)-Mefloquine | 1 |
Most frequently bound compounds
| PDB ligand | Name | Domains in contact |
|---|---|---|
| COA | COENZYME A | 34 |
| ACO | ACETYL COENZYME *A | 29 |
| NAmetal | SODIUM ION | 11 |
| 8MM | (1R,2S,3S,4R,6S)-4,6-diamino-3-{[3-deoxy-4-C-methyl-3-(methylamino)-beta-L-arabinopyranosyl]oxy}-2-hydroxycyclohexyl 2-(acetylamino)-6-amino-2,3,4,6-tetradeoxy-alpha-D-erythro-hexopyranoside | 10 |
| CL | CHLORIDE ION | 6 |
| PAR | PAROMOMYCIN | 6 |
| SOP | [(2R,3S,4R,5R)-5-(6-AMINO-9H-PURIN-9-YL)-4-HYDROXY-3-(PHOSPHONOOXY)TETRAHYDROFURAN-2-YL]METHYL(3R)-3-HYDROXY-2,2-DIMETHYL-4-OXO-4-{[3-OXO-3-({2-[(2-OXOPROPYL)THIO]ETHYL}AMINO)PROPYL]AMINO}BUTYL DIHYDROGENDIPHOSPHATE | 6 |
| P4K | polyethylene glycol | 5 |
| TAR | D(-)-TARTARIC ACID | 5 |
| AKN | (2S)-N-[(1R,2S,3S,4R,5S)-4-[(2R,3R,4S,5S,6R)-6-(aminomethyl)-3,4,5-tris(oxidanyl)oxan-2-yl]oxy-5-azanyl-2-[(2S,3R,4S,5S,6R)-4-azanyl-6-(hydroxymethyl)-3,5-bis(oxidanyl)oxan-2-yl]oxy-3-oxidanyl-cyclohexyl]-4-azanyl-2-oxidanyl-butanamide | 2 |
| NTL | N-[(2S,3R)-2-{[(1R,2S,3S,4R,6S)-6-amino-3-{[3-deoxy-4-C-methyl-3-(methylamino)-beta-L-lyxopyranosyl]oxy}-4-(ethylamino)-2-hydroxycyclohexyl]oxy}-6-(aminomethyl)-3,4-dihydro-2H-pyran-3-yl]acetamide | 2 |
| PZC | (2S)-N-[(1R,2S,3S,4R,5S)-4-{[(2S,3R)-3-(acetylamino)-6-{[(2-hydroxyethyl)amino]methyl}-3,4-dihydro-2H-pyran-2-yl]oxy}-5-amino-2-{[3-deoxy-4-C-methyl-3-(methylamino)-beta-L-arabinopyranosyl]oxy}-3-hydroxycyclohexyl]-4-amino-2-hydroxybutanamide | 2 |
| R7Y | (1S,2S,3R,4S,6R)-3-{[2-(acetylamino)-6-amino-2,3,6-trideoxy-alpha-D-ribo-hexopyranosyl]oxy}-4,6-diamino-2-hydroxycyclohexyl 3-amino-3-deoxy-alpha-D-glucopyranoside | 2 |
| TOY | TOBRAMYCIN | 2 |
| 5LQ | 5-(3-chlorophenyl)-4-methyl-~{N}-(3-morpholin-4-ylpropyl)-1,1-bis(oxidanylidene)-1,2-thiazol-3-amine | 1 |
| 5LR | 5-(4-chlorophenyl)-~{N}-[3-(3,4-dihydro-1~{H}-isoquinolin-2-yl)propyl]-4-methyl-1,1-bis(oxidanylidene)-1,2-thiazol-3-amine | 1 |
| 6E9 | N-(3-methoxyphenyl)-N-methyl-2,3-dioxo-1,2,3,4-tetrahydroquinoxaline-6-sulfonamide | 1 |
| 7LF | 1-(4-fluorophenyl)-2-[2-(4-methylphenyl)-2-oxoethyl]pyrrolo[1,2-a]pyrazin-2-ium | 1 |
| ACM | ACETAMIDE | 1 |
| CJ7 | 8-fluoro-5-methyl-3-{[2-(piperidin-1-yl)ethyl]sulfanyl}-5H-[1,2,4]triazino[5,6-b]indole | 1 |